ArticleJournal of medical virology2025
Hepatitis C Virus Saint Petersburg Variant Detection With Machine Learning Methods.
Article in Journal of medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Hepatitis C virus infection is a significant global health concern, affecting millions worldwide. Although direct-acting antivirals achieve over 90% success rate, treatment failures still occur, particularly when pan-genotypic DAAs are unavailable, and drugs need to be chosen based on the present HCV genotype. Genotyping tests can be misleading, especially in cases involving the 2k/1b recombinant variant. The 2k/1b variant was first discovered in Saint Petersburg in 2002 and is most commonly observed in Eastern European countries, including Russia, Georgia, and Ukraine. Due to migration, the 2k/1b variant has spread to Western Europe and other regions, potentially increasing HCV transmission and changing the virus's epidemiological landscape. The situation highlights the importance of molecular epidemiology in monitoring the spread of the 2k/1b variant. Accurate detection and characterization of the 2k/1b variant are crucial for an effective treatment if no pan-genotypic DAAs are available. To address this need, machine learning models were developed to predict the 2k/1b variant based on 1b and 2k/1b sequence data from nonstructural proteins. They were integrated into the tool, providing physicians and researchers with an open-access resource for determining HCV genotypes, including the 2k/1b variant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.